Skip to main content
. 2018 Jul 16;9(3):255–263. doi: 10.3892/mco.2018.1672

Figure 3.

Figure 3.

mOS in the overall population. The mOS in the overall population treated with Everolimus-Exemestane in combination was 33.0 months (95% confidence interval 25.2-41.2) mOS, median overall survival.